Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

Fig. 4

Cytotoxicity and lytic ability of piggyBac-NK2GD.CAR-NK cells against CD73+ targets. a Mean fluorescence intensity (MFI) of intracellular IFN-γ production by both NK-92 and piggyBac-NKG2D.CAR-NK-92 cells. b Degranulation as measured via CD107a expression (MFI) by both NK-92 and piggyBac-NKG2D.CAR-NK-92 cells. c Lytic activity of NK-92 and piggyBac-NKG2D.CAR-NK-92 cells against CD73+ GBM43, GBM10, A549 or PC3 cells, respectively. Data are presented as the mean ± SEM (n = 4). *P < 0.05, **P < 0.01

Back to article page